Lv1
40 积分 2025-12-17 加入
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
4个月前
已完结
Liver tumour immune microenvironment subtypes and neutrophil heterogeneity
5个月前
已完结
Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes
5个月前
已完结
皖公网安备34019202002308
